Yes, in a randomized trial — for many participants, and for some much longer. In the RIO trial (Imperial College London, University of Oxford, and Rockefeller University), 68 men living with HIV received either two long-acting broadly neutralizing antibodies (bNAbs) — 3BNC117-LS and 10-1074-LS — or a placebo, then paused daily antiretroviral therapy (ART) under close monitoring. About three-quarters of people who got the antibodies had not met the trial’s viral-rebound criteria by 20 weeks, versus roughly one in ten on placebo.
A Nature Medicine analysis of secondary outcomes, covered on September 18, 2026, reported that people who already made their own neutralizing antibodies against HIV controlled the virus longer after bNAb therapy (about 108 weeks on average before restarting ART versus about 27.5 weeks without those autologous antibodies). Intact viral reservoir copies also declined faster after bNAbs than under ART alone. This is not a cure: rebound still occurred for many people, and ART was restarted when needed.
Source: News-Medical / Rockefeller University — Antibody therapy teaches the immune system to control HIV (Sep 18, 2026), summarizing Fumagalli et al., Nature Medicine.